Molecular subtyping of invasive bladder cancer: time to divide and rule?

Cancer Cell. 2014 Feb 10;25(2):135-6. doi: 10.1016/j.ccr.2014.01.026.


Therapeutic decisions for muscle-invasive bladder cancer (MIBC) are largely based on histopathologic characteristics. In this issue of Cancer Cell, Choi and colleagues report three molecular subtypes of MIBC with the potential to guide prognosis, patient stratification, and treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Basal Cell / pathology*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Humans
  • Male
  • Muscle Neoplasms / pathology*
  • Mutation / genetics*
  • Tumor Suppressor Protein p53 / genetics*
  • Urinary Bladder Neoplasms / pathology*


  • TP53 protein, human
  • Tumor Suppressor Protein p53